Insights

Strategic funding NAPIGEN has secured multiple funding streams, including NIH SBIR and seed rounds totaling several million dollars, signaling investor confidence and potential for expanded collaborations or licensing opportunities with public institutes and life science funds.

Organelle tech focus Specialization in mitochondrial and chloroplast genome engineering positions the company for partnerships in biotech, agriculture, and healthcare sectors seeking advanced gene-editing capabilities in energy and biosynthesis pathways.

Diverse applications Broad application areas spanning industrial biotech, agriculture, and human healthcare suggest cross-vertical sales playbooks; identify customers in crop protection, bioenergy, and mitochondrial disease research as near-term targets.

Strategic alliances Funding from disease-focused and research organizations (United Mitochondrial Disease Foundation, NIH SBIR) indicates appetite for collaborations; pursue co-development, grant-funded projects, and sponsored research agreements.

Scale and reach Smaller company size (11-50 employees) coupled with significant revenue and notable investors implies agility with niche offerings; target mid-sized labs, biotech startups, and regional biotech clusters for pilot programs and faster onboarding.

Similar companies to NAPIGEN, INC.

NAPIGEN, INC. Tech Stack

NAPIGEN, INC. uses 8 technology products and services including Amazon Web Services, GoDaddy Website Builder, Microsoft 365, and more. Explore NAPIGEN, INC.'s tech stack below.

  • Cloud Hosting
  • GoDaddy Website Builder
    Content Management System
  • RequireJS
    Javascript Frameworks
  • Polyfill
    Javascript Libraries
  • PWA
    Miscellaneous
  • HSTS
    Security
  • GoDaddy
    Web Hosting

NAPIGEN, INC.'s Email Address Formats

NAPIGEN, INC. uses at least 2 email formats:
NAPIGEN, INC. Email FormatsExamplePercentage
First.Last@napigen.comJohn.Doe@napigen.com
95%
Last@napigen.comDoe@napigen.com
5%

Frequently Asked Questions

What is NAPIGEN, INC.'s official website and social media links?

Minus sign iconPlus sign icon
NAPIGEN, INC.'s official website is napigen.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does NAPIGEN, INC. generate?

Minus sign iconPlus sign icon
As of August 2026, NAPIGEN, INC.'s annual revenue is estimated to be $10M - $25M.

What is NAPIGEN, INC.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
NAPIGEN, INC.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does NAPIGEN, INC. have currently?

Minus sign iconPlus sign icon
As of August 2026, NAPIGEN, INC. has approximately 20 employees across 1 continents, including North America. Key team members include Scientific Advisor: M. S. and Sr.Research Associate: M. H. Explore NAPIGEN, INC.'s employee directory with LeadIQ.

What industry does NAPIGEN, INC. belong to?

Minus sign iconPlus sign icon
NAPIGEN, INC. operates in the Biotechnology Research industry.

What technology does NAPIGEN, INC. use?

Minus sign iconPlus sign icon
NAPIGEN, INC.'s tech stack includes Amazon Web Services, GoDaddy Website Builder, Microsoft 365, RequireJS, Polyfill, PWA, HSTS and GoDaddy.

What is NAPIGEN, INC.'s email format?

Minus sign iconPlus sign icon
NAPIGEN, INC.'s email format typically follows the pattern of First.Last@napigen.com. Find more NAPIGEN, INC. email formats with LeadIQ.

How much funding has NAPIGEN, INC. raised to date?

Minus sign iconPlus sign icon
As of August 2026, NAPIGEN, INC. has raised $7.9M in funding. The last funding round occurred on Mar 11, 2024.

When was NAPIGEN, INC. founded?

Minus sign iconPlus sign icon
NAPIGEN, INC. was founded in 2016.
NAPIGEN, INC. logo

NAPIGEN, INC.

Biotechnology ResearchDelaware, United States11-50 Employees

NAPIGEN, INC. is a biotechnology company based in Wilmington, Delaware, focused on genome engineering across plants, microbes, and animals by targeting organelles that contain their own DNA, specifically mitochondria and chloroplasts. The firm aims to enable the modification of these organelles to influence cellular energy production and the synthesis of biochemical molecules involved in key biological pathways, with applications spanning industrial biotechnology, agriculture, and healthcare. Operating within the biotechnology research sector, NAPIGEN positions itself at the intersection of genome editing and organelle biology to explore new capabilities for modifying cellular function.

Founded and operating from the Delaware region, the company concentrates on developing its organelle-focused genome technology for diverse use cases, including human cells and agricultural systems, while pursuing collaborations and funding sources that support its research trajectory. A notable recent development involves progress in applying its technology to mitochondrial and chloroplast genomes, signaling ongoing work to expand the scope of its platform beyond basic research into potential applied contexts.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $7.9M

    NAPIGEN, INC. has raised a total of $7.9M of funding over 4 rounds. Their latest funding round was raised on Mar 11, 2024 as a Grant.

  • $10M - $25M

    NAPIGEN, INC.'s revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.